NCT05763277

Ate-Bev Early Response Prediction Model in Advanced HCC

Developing Atezolizumab-Bevacizumab Treatment Response Early Prediction Model in Advanced Hepatocellular Carcinoma Patients

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 170 (estimated)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. However, there is no information on the evaluation on the evaluation of treatment response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone or bevacizumab alone. Therefore, this study aimed to create a predictive model that can detect treatment response at an early stage.

Conditions

• Hepatocellular Carcinoma
• Atezolizumab-bevacizumab
• Response Evaluation

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Early response evaluation	Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).

Timeline

• Start date: 2022-07-22
• Primary completion: 2025-12-31
• Completion: 2026-12-31
• First posted: 2023-03-10
• Last updated: 2025-05-15

Locations

1 site across 1 country: South Korea